Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting

Transplant International

Volumn 28, Issue 9, 2015, Pages 1011-1024

  Beinhardt, Sandra ^a   Peck Radosavljevic, Markus ^a   Hofer, Harald ^a   Ferenci, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

cirrhosis compensated; decompensated; direct acting antivirals; fibrosing cholestatic hepatitis; HCV recurrence; liver transplantation; recommendations; treatment guidelines

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; ELBASVIR; GRAZOPREVIR; INTERFERON; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON ALPHA; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ABT-267; ABT-333; ABT-450; ANILIDE; CARBAMIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MACROCYCLIC COMPOUND; SULFONAMIDE; URACIL;

ANTIVIRAL THERAPY; AREA UNDER THE CURVE; CHILD PUGH SCORE; CHRONIC HEPATITIS C; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT INFECTION; REVIEW; TREATMENT PLANNING; VIRAL CLEARANCE; ANALOGS AND DERIVATIVES; CHOLESTASIS, INTRAHEPATIC; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DRUG INTERACTION; FIBROSIS; HEPACIVIRUS; HEPATITIS C, CHRONIC;

ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; CHOLESTASIS, INTRAHEPATIC; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FIBROSIS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MACROCYCLIC COMPOUNDS; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SULFONAMIDES; URACIL;

EID: 84938739029     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12577     Document Type: Review

References (79)

1. Adam R, McMaster P, ÓGrady JG, et al,. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 1231.
2. Kim WR,. The burden of hepatitis C in the United States. Hepatology 2002; 36 (5 Suppl. 1): S30.
3. Belli LS, Burroughs AK, Burra P, et al,. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007; 13: 733.
4. Berenguer M, Ferrell L, Watson J, et al,. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673.
5. Yilmaz N, Shiffman ML, Stravitz RT, et al,. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13: 975.
6. Walter T, Dumortier J, Guillaud O, Hervieu V, Scoazce JY, Boillot O,. Factors after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center. Liver Transpl 2007; 13: 294.
7. Neumann UP, Berg T, Bahra M, et al,. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830.
8. Forman LM, Lewis JD, Berlin JA, Feldmann HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
9. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274.
10. Gambato M, Lens S, Navasa M, Forns X,. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol 2014; 61: 120.
11. Hézode C, Fontaine H, Dorival C, et al,. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132.
12. Rutter K, Ferlitsch A, Maieron A, et al,. Safety of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced disease-predictive factors for sepsis. J Hepatol 2013; 58 (Suppl): S30.
13. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X,. The effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20.
14. Forns X, Samuel D, Mutimer D, et al,. Interim SVR12 results from the telaprevir phase3B REPLACE study in treatment-naive stable liver transplant patients with genotype 1 HCV infection. J Hepatol 2014; 60: S481.
15. AASLD: Recommendations for Testing, Managing, and Treating Hepatitis C. December 2014. http://www.hcvguidelines.org
16. EASL: Recommendations on Treatment of Hepatitis C. April 2014. http://www.easl.eu
17. Poordad F, McCone Jr J, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195.
18. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405.
19. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 364: 1014.
20. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207.
21. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for treatment of HCV infection. N Engl J Med 2011; 364: 2417.
22. Afdhal N, Zeuzem S, Kwo P, et al,. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889.
23. Afdhal N, Reddy KR, Nelson DR, et al,. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483.
24. Bourliere M, Bronowicki J, de Ledinghen V, et al,. Ledipasvir/Sofosbuvir Fixed Dose Combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. Hepatology 2014; 60: 1270.
25. Poordad F, Hezode C, Trinh R, et al,. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973.
26. Manns M, Pol S, Jacobson IM, et al,. All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: phase 3 study results. Lancet 2014; 384: 1597.
27. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878.
28. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867.
29. Zeuzem S, Dusheiko GM, Salupere R, et al,. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993.
30. Nelson DR, Cooper JN, Lalezari JP, et al,. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology 2015; 61: 1127.
31. Gane EJ, Hyland RH, An D, et al,. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology 2014; 60: 1274A.
32. Curry MP, Forns X, Chung RT, et al,. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 100.
33. Afdhal N, Everson G, Calleja JL, et al,. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatol 2014; 60 (Suppl. 1): S28.
34. Flamm SL, Everson GT, Charlton M, et al,. Ledipasvir/Sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 2014; 60 (Suppl. 1): 320A.
35. Ruiz I, Feray C, Pawlotsky JM, Hezode C,. Patient with decompensated hepatitis C virus-related cirhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver Transpl 2015; 21: 408.
36. Fontana RJ, Hughes EA, Bifano M, et al,. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 6: 1601.
37. Pellicelli AM, Montalbano M, Lionetti R, et al,. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014; 46: 923.
38. Charlton M, Gane E, Manns MP, et al,. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108.
39. Forns X, Charlton M, Denning J, et al,. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2014. doi: 10.1002/hep.27681 [epub ahead of print].
40. Pungapong S, Aqel B, Leise M, et al,. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015. doi: 10.1002/hep.27770. [Epub ahead of print].
41. Jensen DM, ÓLeary JG, Pockros PJ, et al,. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. Hepatology 2014; 60 (Suppl. 1): 219A.
42. Kwo PY, Mantry PS, Coakley E, et al,. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375.
43. Reddy RK, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Sarif T,. Ledipasvir/Sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. Hepatology 2014; 60 (Suppl. 1): 200.
44. Ouwerkerk-Mahadevan M, Simion A, Spittaels K, Beumont-Mauviel M,. Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment J. Hepatology 2013; 58: S365.
45. Khatri A, Gaultier IA, Menon R, et al,. Pharmacokinetics and safety of coadministered ABT-450 plus ritonavir(ABT-450/r), ABT-267 and ABT-333 as a single dose in subjects with normal hepatic function and in subjects with mild, moderate, and sever hepatic impairment. Hepatology 2012; 56 (Suppl. 1): 555.
46. Beinhardt S, Staettermayer AF, Rutter K, et al,. Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias? Hepatology 2012; 55: 30.
47. Ruiz I, Feray C, Pawlotsky JM, Hezode C,. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver Transpl. 2015; 21: 408.
48. Coilly A, Furlan V, Roche B, et al,. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipient with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012; 56: 5728.
49. Osinusi A, Meissner EG, Lee YJ, et al,. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804.
50. Gane EJ, Stedman CA, Hyland RH, et al,. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A Inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastronenterology 2013; 146: 736.
51. Lawitz E, Poordad FF, Pang PS, et al,. Sofosbuvir and ledipasvir fixed-dose combination with and without rivavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2013; 383: 515.
52. Lawitz E, Sulkowsky MS, Ghalib R, et al,. Simeprevir plus sofosbuvir, with or without rivavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756.
53. Zeuzem S, Soriano V, Asselah T, et al,. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630.
54. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al,. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211.
55. Ruane PJ, Ain D, Stryker R, et al,. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015; 62: 1040.
56. Brown RS, Reddy KR, ÓLeary JG, et al,. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. Hepatology 2014; 60: 1269.
57. Leroy V, Dumortier IJ, Coilly A, et al,. High rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regimens for the treatment of fibrosing cholestatic HCV-recurrence after liver transplantation: the ANRS CO23 CUPILT study. Hepatology 2014; 60 (Suppl. 1): 207.
58. Conti F, Lebray P, Schielke A, et al,. Sofosbuvir/Daclatasvir therapy for recurrent hepatitis C after liver transplantation: preliminary report from the parisian centers. Hepatology 2014; 60 (Suppl. 1): 208.
59. Jensen DM, O'Leary JG, Pockros PJ, et al,. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. Hepatology 2014; 60 (Suppl. 1): 219.
60. Satoskar R, Ahn J, Te HS, et al,. Sofosbuvir as the backbone of treatment for HCV after liver transplantation: a real-life multicenter experience. Hepatology 2014; 60 (Suppl. 1): 537.
61. Bzowej NH, Joshi S, Therapondos G, et al,. Post-transplant treatment of severe recurrent hepatitis C (HCV) with daclatasvir and sofosbuvir plus or minus ribavirin. Hepatology 2014; 60 (Suppl. 1): 542.
62. Gordon FD, Kosinski AL, Coombs SJ, Goucher P, Aljahdli ES, Pomfret EA,. Sofosbuvir + simeprevir is safe in liver transplant recipients. Hepatology 2014; 60 (Suppl. 1): 543.
63. Gutierrez JA, Grigorian A, Carrion AF, et al,. Safety and efficacy of hepatitis C therapy with sofosbuvir and simeprevir after liver transplantation. Hepatology 2014; 60 (Suppl. 1): 545.
64. Suliman I, Pozza R, Kady Y, et al,. The combination of simeprevir and sofosbuvir for the treatment of HCV infection in patients post liver transplant with significant fibrosis. Hepatology 2014; 60 (Suppl. 1): 545.
65. Nair S, Dbouk N, Lingala S, Satapathy SK,. Safety and efficacy of simeprevir, sofosbuvir and ribavirin combination therapy in liver transplant recipients with severe recurrent HCV. Hepatology 2014; 60 (Suppl. 1): 681.
66. Ripper SJ, Holt EW, Cooper S, et al,. Simeprevir plus sofosbuvir for patients with recurrence of genotype 1 hepatitis C infection after liver transplantation. Hepatology 2014; 60 (Suppl. 1): 684.
67. Punzalan CS, Barry C, Zacharias I, et al,. Successful treatment of post liver transplant patients with genotype 1 hepatitis C virus with sofosbuvir and simeprevir. Hepatology 2014; 60 (Suppl. 1): 688.
68. Papadopoulos-Köhn A, Timm J, Canbay A, et al,. Daclatasvir, Simeprevir and Ribavirin as a new IFN-free triple regimen for HCV recurrence after liver transplantation: first results of safety and efficacy in 6 patients. Hepatology 2014; 60 (Suppl. 1): 697.
69. Crittenden N, Davis E, Marsano LS, et al,. Single center experience with simeprevir/sofosbuvir combination therapy for recurrent hepatitis C virus infection in liver transplant recipients. Hepatology 2014; 60 (Suppl. 1): 700.
70. Yaseen Alsabbagh ME, Hanouneh IA, John BV, et al,. Safety and efficacy of all-oral sofosbuvir-based regimens to treat HCV recurrence post-liver transplantation. Hepatology 2014; 60 (Suppl. 1): 700.
71. Ford RM, Pillai A, Cheng N, et al,. Post-liver transplant treatment of hepatitis C with a combination of Sofosbuvir, Simeprevir +/- Ribavirin at a High Volume Academic Transplant Center. Hepatology 2014; 60 (Suppl. 1): 701.
72. Kozbial K, Strassl RP, Al-Zoairy R, et al,. Early viral kinetics during Interferon-free Sofosbuvir containing treatment regimen in a real-life cohort of chronic hepatitis C patients. Hepatology 2014; 60 (Suppl. 1): 701.
73. O'Dell H, Raiford DS, Scanga A, Chung CY, Perri R,. Combination of sofosbuvir and simeprevir is very effective and well tolerated for the treatment of recurrent Hepatitis C after liver transplant. Hepatology 2014; 60: 1272.
74. Andreone P, Vukotic R, Fagiuoli S, et al,. Sofosbuvir for the treatment of severe HCV recurrence after liver transplantation: interim results of the AISF-SOFOLT Italian compassionate use program. Hepatology 2014; 60: 1273.
75. Seifert LL, Vorona E, Schmidt HH,. Regression of fibrosis in interferon-free sofosbuvir-based anti-HCV therapy after liver transplantation. Hepatology 2014; 60: 1277.
76. Fontana RJ, Herzer K, Ferenci P, et al,. High efficacy and favorable safety profile of Daclatasvir based all oral antiviral therapy in liver transplant recipients with severe recurrent HCV. Hepatology 2014; 60: 1281.
77. Londoño M, Herzer K, Moreno C, et al,. Safety and efficacy of Simeprevir in combination with Daclatasvir or Sofosbuvir in patients with severe hepatitis C recurrence after liver transplantation: results from compassionate use in Europe. Hepatology 2014; 60: 1287.
78. Miro JM, Stock P, Teicher E, Duclos-Vallee JC, Terrault N, Rimola A,. Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 Update. J Hepatol 2015; 62: 701.
79. Coilly A, Roche B, Duclos-Vallee JC, Samuel D,. Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals. Liver Int 2015; 35 (Suppl. 1): 44.